N
Neograft Technologies
Biotech & Life Sciences · Taunton, United States · Founded 2009
Neograft Technologies – Advanced technology for coronary artery bypass graft surgery MoreLess
Neograft Technologies is a medical device company focused on improving the outcomes of coronary artery bypass grafting (CABG) surgery. The company is developing the Angioshield, a device that creates a supportive, micro-fibrous polymer mesh around a harvested saphenous vein graft.
This external sleeve is applied during the surgical procedure and is designed to improve the vein's durability and performance when used as a bypass conduit. The technology aims to address the common issue of vein graft failure, which can lead to repeat procedures and increased patient risk. The company's primary market is cardiac surgery, serving hospitals and surgical teams that perform heart bypass procedures.
Keywords: medical devices, cardiac surgery, coronary artery bypass grafting, CABG, saphenous vein graft, Angioshield, polymer mesh, cardiovascular, surgical technology, graft failure
Talent graph
Neograft Technologies's talent
Source: Dealroom Talent Intelligence.
Investors
1 investor on Neograft Technologies's cap table
Sourced from Dealroom's funding and investor records.

Global footprint
Where Neograft Technologies has talent and traffic
Market sentiment
What the market is saying about Neograft Technologies
An AI-synthesized read of the highest-engagement posts about Neograft Technologies on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neograft Technologies on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.